Etanercept induced multiple sclerosis and transverse myelitis.
Al Saieg
Nawar
N
Luzar
Michael J
MJ
D018501:Antirheumatic Agents / Q000009:adverse effects*; D001921:Brain / Q000473:pathology; D000068800:Etanercept; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008279:Magnetic Resonance Imaging; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D009188:Myelitis, Transverse / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor; D013116:Spinal Cord / Q000473:pathology; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D005938:Glucocorticoids; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept; D008775:Methylprednisolone